References
1. Favier J, Amar L, Gimenez-Roqueplo AP. 2015. Paraganglioma and
phaeochromocytoma: from genetics to personalized medicine. Nat Rev
Endocrinol. 11 (2): 101-111.
2. Maher ER, Neumann HP, Richard S. 2011. von Hippel-Lindau disease: a
clinical and scientific review. Eur J Hum Genet. 19 (6): 617-623.
3. Lloyd R, Osamura R, Klöppel G, Rosai J. WHO Classification of Tumours
of Endocrine Organs, 4th edn IARC Press. Lyon: 2017.
4. Koh JM, Ahn SH, Kim H, et al. 2017. Validation of pathological
grading systems for predicting metastatic potential in pheochromocytoma
and paraganglioma. PLoS One. 12 (11): e0187398.
5. Wachtel H, Hutchens T, Baraban E, et al. 2020. Predicting Metastatic
Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS
and GAPP Scoring Systems. J Clin Endocrinol Metab. 105 (12).
6. Pierre C, Agopiantz M, Brunaud L, et al. 2019. COPPS, a composite
score integrating pathological features, PS100 and SDHB losses, predicts
the risk of metastasis and progression-free survival in
pheochromocytomas/paragangliomas. Virchows Arch. 474 (6):
721-734.
7. Niemeijer ND, Alblas G, van Hulsteijn LT, Dekkers OM, Corssmit EP.
2014. Chemotherapy with cyclophosphamide, vincristine and dacarbazine
for malignant paraganglioma and pheochromocytoma: systematic review and
meta-analysis. Clin Endocrinol (Oxf). 81 (5): 642-651.
8. Pryma DA, Chin BB, Noto RB, et al. 2019. Efficacy and Safety of
High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced
Pheochromocytoma or Paraganglioma. J Nucl Med. 60 (5): 623-630.
9. Satapathy S, Mittal BR, Bhansali A. 2019. ’Peptide receptor
radionuclide therapy in the management of advanced pheochromocytoma and
paraganglioma: A systematic review and meta-analysis’. Clin Endocrinol
(Oxf). 91 (6): 718-727.
10. Kohlenberg J, Welch B, Hamidi O, et al. 2019. Efficacy and Safety of
Ablative Therapy in the Treatment of Patients with Metastatic
Pheochromocytoma and Paraganglioma. Cancers (Basel). 11 (2).
11. Fassnacht M, Assie G, Baudin E, et al. 2020. Adrenocortical
carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol.31 (11): 1476-1490.
12. Ma X, Li M, Tong A, et al. 2020. Genetic and Clinical Profiles of
Pheochromocytoma and Paraganglioma: A Single Center Study. Front
Endocrinol (Lausanne). 11 : 574662.
Table 1. Endocrine function workup results in 2015 revealed no
remarkable abnormality.